Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Guardant Health (GH – Research Report), Argenx Se (ARGX – Research Report) and Annexon Biosciences (ANNX – Research Report).
Guardant Health (GH)
Scotiabank analyst Sung Ji Nam maintained a Buy rating on Guardant Health today and set a price target of $47.00. The company’s shares closed last Monday at $23.75.
According to TipRanks.com, Nam is a 1-star analyst with an average return of
Guardant Health has an analyst consensus of Strong Buy, with a price target consensus of $35.00, a 54.2% upside from current levels. In a report issued on April 29, Canaccord Genuity also maintained a Buy rating on the stock with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
Argenx Se (ARGX)
Scotiabank analyst George Farmer reiterated a Hold rating on Argenx Se today and set a price target of $408.00. The company’s shares closed last Monday at $370.27.
According to TipRanks.com, Farmer is a 4-star analyst with an average return of
Argenx Se has an analyst consensus of Moderate Buy, with a price target consensus of $475.74, which is a 27.3% upside from current levels. In a report issued on May 10, UBS also maintained a Hold rating on the stock with a $410.00 price target.
Annexon Biosciences (ANNX)
In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Annexon Biosciences, with a price target of $16.00. The company’s shares closed last Monday at $4.92.
According to TipRanks.com, Stringer is a 2-star analyst with an average return of
Currently, the analyst consensus on Annexon Biosciences is a Strong Buy with an average price target of $16.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GH:
